Bais C et al. -The combination of bevacizumab and frontline chemotherapy improved progression-free survival, but not overall survival in the GOG-0218 trial. In the current study a positive association was demonstrated between the density of vascular endothelial cells and tumor VEGF-A levels, and the degree of bevacizumab effect in ovarian cancer. The predictive value of MVD (CD31) and tumor VEGF-A is consistent with VEGF-A signaling blockade.